Astellas
Astellas teams up with UK biotech Mogrify on hearing loss project
Phil Taylor
Astellas, cell therapy, hearing loss, Mogrify, otology, partnering, Regenerative medicine
0 Comment
Astellas pumps $90m into Sutro immuno-oncology alliance
Phil Taylor
antibody-drug conjugate, Astellas, immuno-oncology, Oncology, partnering, Sutro Biopharma
0 Comment
Another Astellas gene therapy hits a safety hurdle
Phil Taylor
Astellas, gene therapy, Pompe disease, safety
0 Comment
NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease
Phil Taylor
anaemia, Astellas, chronic kidney disease, Evrenzo, HEOR, NHS, NICE
0 Comment
News/ News/ News/ Oncology/ R&D
EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track
Phil Taylor
acute myeloid leukaemia, Astellas, Daiichi Sankyo, EHA 2022, FLT3 inhibitor, Novartis, quizartinib, Rydapt, Xospata
0 Comment
News/ News/ News/ Oncology/ R&D
Astellas taps GO’s glycoprotein platform with $783.5m deal
Phil Taylor
Astellas, glycoprotein, GO Therapeutics, immuno-oncology, Oncology, partnering
0 Comment
Astellas takes $170m charge as it drops DMD gene therapies
Phil Taylor
Astellas, Duchenne muscular dystrophy, gene therapy, safety
0 Comment
Deep Dive/ R&D/ Views & Analysis
Inside the changing tides of life science research
mike.hammerton@pharmaphorum.com
Astellas, Bernhardt Zeiher, Deep Dive, Deep Dive: Research and Development, research and development
0 Comment